​

Barinthus Biotherapeutics (BRNS) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChart

BRNS Stock Forecast

Barinthus Biotherapeutics (BRNS) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $3.00, with a high of $3.00 and a low of $3.00. This represents a 108.33% increase from the last price of $1.44.

High: $3 Avg: $3 Low: $3 Last Closed Price: $1.44

BRNS Stock Rating

Barinthus Biotherapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

BRNS Price Target Upside V Benchmarks

TypeNameUpside
StockBarinthus Biotherapeutics108.33%
SectorHealthcare Stocks 19.91%
IndustryBiotech Stocks 55.52%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$3.00
Last Closing Price$1.44$1.44$1.44
Upside/Downside--108.33%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2512---3
Jun, 2512---3
May, 2512---3
Apr, 2512---3
Mar, 2512---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 13, 2025Yi ChenH.C. Wainwright$3.00$1.15160.87%108.33%
Jun 13, 2024Yi ChenH.C. Wainwright$5.00$1.87167.38%247.22%
Jun 13, 2024Carter GouldBarclays$3.00$1.9057.89%108.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 24, 2025Alliance Global PartnersBuyBuyhold
Jan 13, 2025H.C. WainwrightBuyBuyhold
Aug 13, 2024Alliance Global PartnersBuyBuyhold
Jun 13, 2024H.C. WainwrightBuyBuyhold
Jun 13, 2024BarclaysOverweightOverweighthold
May 20, 2024Alliance Global PartnersBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-1.37$0.14$-1.91$-1.55---
Avg Forecast$-1.94$0.26$-2.03$-1.48$-1.44$-1.77$-1.99
High Forecast$-1.94$0.26$-1.87$-1.41$-1.20$-1.77$-1.99
Low Forecast$-1.94$0.26$-2.27$-1.54$-1.67$-1.77$-1.99
Surprise %-29.38%-46.15%-5.91%4.73%---

Revenue Forecast

$0 $9M $18M $27M $36M $45M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$268.00K$44.70M$802.00K$14.97M---
Avg Forecast$514.50K$41.35M$810.00K$9.98M$500.00K$738.66K$185.76K
High Forecast$514.50K$41.35M$1.34M$9.98M$500.00K$738.66K$185.76K
Low Forecast$514.50K$41.35M$488.38K$9.98M$500.00K$738.66K$185.76K
Surprise %-47.91%8.10%-0.99%50.00%---

Net Income Forecast

$-90M $-70M $-50M $-30M $-10M $10M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-50.87M$5.34M$-73.35M$-61.07M---
Avg Forecast$-74.60M$9.87M$-77.73M$-56.68M$-55.13M$-68.04M$-76.42M
High Forecast$-74.60M$9.87M$-71.84M$-54.22M$-45.88M$-68.04M$-76.42M
Low Forecast$-74.60M$9.87M$-87.31M$-59.15M$-63.97M$-68.04M$-76.42M
Surprise %-31.82%-45.90%-5.64%7.75%---

BRNS Forecast FAQ

Is Barinthus Biotherapeutics stock a buy?

Barinthus Biotherapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Barinthus Biotherapeutics is a favorable investment for most analysts.

What is Barinthus Biotherapeutics's price target?

Barinthus Biotherapeutics's price target, set by 4 Wall Street analysts, averages $3 over the next 12 months. The price target range spans from $3 at the low end to $3 at the high end, suggesting a potential 108.33% change from the previous closing price of $1.44.

How does Barinthus Biotherapeutics stock forecast compare to its benchmarks?

Barinthus Biotherapeutics's stock forecast shows a 108.33% upside, outperforming the average forecast for the healthcare stocks sector (19.91%) and outperforming the biotech stocks industry (55.52%).

What is the breakdown of analyst ratings for Barinthus Biotherapeutics over the past three months?

  • July 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Barinthus Biotherapeutics’s EPS forecast?

Barinthus Biotherapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.44, marking a -7.10% decrease from the reported $-1.55 in 2024. Estimates for the following years are $-1.77 in 2026, and $-1.99 in 2027.

What is Barinthus Biotherapeutics’s revenue forecast?

Barinthus Biotherapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $500K, reflecting a -96.66% decrease from the reported $14.97M in 2024. The forecast for 2026 is $738.66K, and $185.76K for 2027.

What is Barinthus Biotherapeutics’s net income forecast?

Barinthus Biotherapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-55.135M, representing a -9.73% decrease from the reported $-61.074M in 2024. Projections indicate $-68.042M in 2026, and $-76.424M in 2027.